My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Farmacia Hospitalaria
On-line version ISSN 2171-8695Print version ISSN 1130-6343
Abstract
MEJUTO, Beatriz; CASTELLANO, Paloma; CASTRO, Concepción and LOPEZ, Luis Manuel. Assessment of the efficacy and safety of fampridine. Farm Hosp. [online]. 2017, vol.41, n.2, pp.283-291. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.2017.41.2.10615.
Objective:
Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.
Method:
A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial.
Results:
Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects.
Conclusions:
The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking.
Keywords : Fampridine; Multiple sclerosis; Efficacy; Safety.